Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma

Bone Marrow Transplantation

Volumn 39, Issue 12, 2007, Pages 743-750

  Fruehauf, S ^a,b   Klaus, J ^b   Huesing, J ^c   Veldwijk, M R ^b,d   Buss, E C ^b   Topaly, J ^b   Seeger, T ^b,d   Zeller, L W J ^d   Moehler, T ^b   Ho, A D ^b   Goldschmidt, H ^b  

^a Paracelsus Klinik Osnabruck   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Department of Oncology and Hematology   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IDARUBICIN; MELPHALAN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; APHERESIS; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CD34 SELECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; LEUKOCYTE COUNT; MALE; MULTIPLE MYELOMA; NAUSEA; PERIPHERAL BLOOD STEM CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; THORAX PAIN; THROMBOCYTE COUNT;

ADULT; AGED; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD COMPONENT REMOVAL; CELL COUNT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FEMALE; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; POLYETHYLENE GLYCOLS;

EID: 34250196065     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705675     Document Type: Article

References (24)

1. Harousseau JL, Moreau P. Evolving role of stem cell transplantation in multiple myeloma. Clin Lymphoma Myeloma 2005; 6: 89-95 (Review).
2. Watts MJ, Ings SJ, Leverett D, MacMillan A, Devereux S, Goldstone AH et al. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: A matched pairs analysis of 78 patients. Br J Cancer 2000; 82: 278-282.
3. Zamboni WC. Pharmacokinetics of pegfilgrastim. Pharmacotherapy 2003; 23: 9S-14S.
4. Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20: 727-731.
5. Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P et al. International Pegfilgrastim 749 Study Group. A randomized, double-blind, multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29-35.
6. Siena S, Piccart MJ, Holmes FA, Glaspy J, Hackett J, Renwick JJ. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II-IV breast cancer. Oncol Rep 2003; 10: 715-724.
7. Wolf T, Densmore JL. Pegfilgrastim use during chemotherapy: Current and future applications. Curr Hematol Rep 2004; 3: 419-423.
8. Isidori A, Tani M, Bonifazi F, Zinzani P, Curti A, Rosa Motta M et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 2005; 90: 225-231.
9. Russell N, Mesters R, Pfreundschuh M, Boogaerts M, Johnsen H, del Canizo M et al. Pegfilgrastim (6mg or 12 mg) mobilises CD34+ cells similarly to filgrastim (5 μg/kg/day) when administered following chemotherapy in patients with non-Hodgkin's lymphoma. Blood 2005; 106: 560a (Abstract 1977).
10. Steidl U, Fenk R, Bruns I, Neumann F, Kondakci M, Hoyer B et al. Successful transplantation of peripheral blood stem cells mobilised by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2005; 35: 33-36.
11. Noga SJ, Oroszlan M, Zhang YL, Kassa MB, Hetherington J, Feldman MJ et al. Single dose pegfilgrastim successfully mobilises optimal numbers of autologous CD34+ cells for peripheral blood stem cell collection. Blood 2002; 100: 826a, Abstract 3262.
12. Noga S, Oroszlan M, Hetherington J. Use of pegfilgrastim for autologous peripheral blood stem cell mobilisation: Comparison to a daily filgrastim regimen. Bone Marrow Transplant 2003; 31: S18.
13. Kroschinsky F, Holig K, Platzbecker U, Haack A, Schaich M, Bornhauser M. Pegfilgrastim is able to mobilize autologous CD34+ peripheral blood progenitor cells in patients with lymphoid malignancies and solid tumors. Bone Marrow Transplant 2004; 33: S79 (Abstract P408).
14. Mandanas RA, Underwood BJ, Geister BV, Smith JW. Pegfilgrastim (Neulasta) following chemotherapy leads to successful mobilisation of hematopoietic progenitor cells among transplant patients with various diagnoses. Biol Blood Marrow Transplant 2004; 10: 14 (Abstract 21).
15. Hosing C, Qazilbash MH, Kebriaei P, Giralt S, Davis MS, Popat U et al. Fixed dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br J Haematol 2006; 133: 533-537.
16. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213-226.
17. Bauer DF. Constructing confidence sets using rank statistics. J Am Stat Assoc 1972; 67: 687-690.
18. Haas R, Witt B, Mohle R, Goldschmidt H, Hohaus S, Fruehauf S et al. Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support. Blood 1995; 85: 3754-3761.
19. Fenk R, Hieronimus N, Steidl U, Bruns I, Graef T, Zohren F et al. Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. Exp Hematol 2006; 34: 1296-1302.
20. Kroschinsky F, Hoelig K, Platzbecker U, Poppe-Thiede K, Ordemann R, Blechschmidt M et al. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilisation of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma. Transfusion 2006; 46: 1417-1423.
21. Morris ES, MacDonald KP, Hill GR. Stem cell mobilisation with G-CSF analogs: A rational approach to separate GVHD and GVL? Blood 2006; 107: 3430-3435.
22. Seggewiss R, Buss E, Herrmann D, Goldschmidt H, Ho AD, Fruehauf S. Kinetics of peripheral blood stem cell mobilisation following G-CSF-supported chemotherapy. Stem Cells 2003; 21: 568-574.
23. Bruns I, Steidl U, Kronenwett R, Fenk R, Graef T, Rohr UP et al. A single dose of 6 to 12mg of pegfilgrastim for peripheral blood progenitor cell mobilisation results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 2006; 46: 180-185.
24. Goertz A, Dubois RW, Doan QV, Liu Z, Heissel A, von Minckwitz G. Primary prophylaxis against febrile neutropenia with pegfilgrastim is more cost effective than filgrastim in women with breast cancer receiving chemotherapy in Germany. ISPOR 9th Annual European Congress 2006, Copenhagen, Denmark; Abstract: PIN6.